LTR Pharma’s $25 million placement to support the commercialisation of SPONTAN – its fast-acting nasal spray treatment for erectile dysfunction (ED) – has been reported in The Australia, in a special report titled ‘LTR Pharma successfully completes $25m cap raise to accelerate novel ED treatment.’
Here’s an excerpt:
“LTR Pharma chairman Lee Rodne said the successful $25m placement was underscored by strong support from institutional investors.
“This funding is a critical milestone for LTR Pharma as we advance towards commercialising Spontan in the US, Australia and other key markets,” he said.”
The company is now funded through until the end of 2026, which includes key upcoming value-creating milestones as Spontan advances towards commercialisation.